abacavir sulfate; dolutegravir sodium; lamivudine · Viiv Hlthcare · NDA 215413
Triumeq Pd
Earliest generic entry, as listed
8 Jun 2030
Blocked by patent: US 9242986.
Listed patents · 4 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 9242986 | — | 8 Jun 2030 |
| US 9242986 | substance, product | 8 Dec 2029 |
| US 8129385 | — | 5 Apr 2028 |
| US 8129385 | substance, product | 5 Oct 2027 |
Exclusivities · 1 unexpired
| PED | pediatric (6 months added) | 15 Dec 2026 |
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
- 24 Oct 2026Exclusivity expires within 90 days PED · 215413-00115 Dec 2026
Products covered · 1
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 215413 · 001 · RLD | tablet, for suspension, oral | EQ 60MG BASE;EQ 5MG BASE;30MG | 8 Jun 2030 |
Expired or delisted (1)
- NPP · 15 Jun 2026